Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effect of methylprednisolone versus placebo on the risk of acute kidney injury in a subsample of patients with serial postoperative serum creatinine assessments.

Published byそうりん さわなか Modified over 5 years ago

Similar presentations

Presentation on theme: "Effect of methylprednisolone versus placebo on the risk of acute kidney injury in a subsample of patients with serial postoperative serum creatinine assessments."— Presentation transcript:

1 Effect of methylprednisolone versus placebo on the risk of acute kidney injury in a subsample of patients with serial postoperative serum creatinine assessments (restricted to the 4824 patients who were randomly assigned on or after Mar. 1, 2012). Effect of methylprednisolone versus placebo on the risk of acute kidney injury in a subsample of patients with serial postoperative serum creatinine assessments (restricted to the 4824 patients who were randomly assigned on or after Mar. 1, 2012)‏ Amit X. Garg et al. CMAJ 2019;191:E247-E256 ©2019 by Canadian Medical Association

Download ppt "Effect of methylprednisolone versus placebo on the risk of acute kidney injury in a subsample of patients with serial postoperative serum creatinine assessments."

Similar presentations

The Diagnostic and Statistical Manual of Mental Disorders.

The Diagnostic and Statistical Manual of Mental Disorders.
The Diagnostic and Statistical Manual of Mental Disorders.

The Diagnostic and Statistical Manual of Mental Disorders.
Acute Kidney Injury. 100,000 deaths are year are associated with acute kidney injury. (NCEPOD 2009)

Acute Kidney Injury. 100,000 deaths are year are associated with acute kidney injury. (NCEPOD 2009)
RIFLE criteria for acute kidney injury

RIFLE criteria for acute kidney injury
AKI alerts on ICE at the Luton and Dunstable Hospital

AKI alerts on ICE at the Luton and Dunstable Hospital
Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110: 3512-3517.

Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110:
Mean scores for symptoms of mental illness between 1994/95 and 2004/05 in participants aged 10–11 years (A), between 1996/97 and 2007/08 in those aged.

Mean scores for symptoms of mental illness between 1994/95 and 2004/05 in participants aged 10–11 years (A), between 1996/97 and 2007/08 in those aged.
Association between Continuous Peri-procedural Use of ACE Inhibitors or ARBs in Patients with AKI Undergoing Cardiac Catheterization Bin Hu, M.D, Usman.

Association between Continuous Peri-procedural Use of ACE Inhibitors or ARBs in Patients with AKI Undergoing Cardiac Catheterization Bin Hu, M.D, Usman.
Primary end point of the ANZICS low-dose dopamine trial

Primary end point of the ANZICS low-dose dopamine trial
Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.
Supplementary Figure 1 Shiota et al.

Supplementary Figure 1 Shiota et al.
Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.
Figure 4 Interplay between acute kidney injury (AKI),

Figure 4 Interplay between acute kidney injury (AKI),
Results of random-effects meta-analysis of association between use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers and.

Results of random-effects meta-analysis of association between use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers and.
Figure 6 Differences in glycaemic control with the study drug

Figure 6 Differences in glycaemic control with the study drug
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Jeremiah S. Hinson, MD, PhD, Michael R. Ehmann, MD, MPH, MS, Derek M

Jeremiah S. Hinson, MD, PhD, Michael R. Ehmann, MD, MPH, MS, Derek M
Volume 89, Issue 6, Pages (June 2016)

Volume 89, Issue 6, Pages (June 2016)
Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.
Figure 1 Acute kidney injury and chronic kidney disease

Figure 1 Acute kidney injury and chronic kidney disease

Similar presentations

Ads by Google